Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
Crossref DOI link: https://doi.org/10.1007/s12020-016-0978-6
Published Online: 2016-05-21
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Findling, James W.
Fleseriu, Maria
Newell-Price, John
Petersenn, Stephan
Pivonello, Rosario
Kandra, Albert
Pedroncelli, Alberto M.
Biller, Beverly M. K.
Funding for this research was provided by:
Novartis Pharma AG
License valid from 2016-05-21